Centauri Therapeutics
Clinical-stage immunotherapy company developing a modular bifunctional therapeutic platform that recruits endogenous anti-glycan antibodies to treat life-threatening infections and other high‑unmet-need indications. The company’s lead programme (ABX-01) has progressed from lead optimisation through preclinical development into first-in-human studies and has secured regulatory and grant support to accelerate development.
Industries
Nr. of Employees
small (1-50)
Centauri Therapeutics
London, England, United Kingdom
Patents
Products
CTX-187 (lead clinical candidate, ABX-01 programme)
Lead clinical-stage bifunctional antimicrobial immunotherapy designed to treat clinically prevalent and multidrug-resistant Gram-negative bacterial infections; combines direct antibacterial activity with recruitment of anti-glycan antibodies to activate complement and opsonophagocytosis. Progressed into Phase I clinical trials (first-in-human) and received QIDP designation.
CTX-09 (early proof-of-concept molecule)
Preclinical bifunctional molecule that demonstrated recruitment of anti‑glycan antibodies and immune‑mediated clearance of multidrug‑resistant Gram‑negative strains in vitro and in vivo; published in a peer‑reviewed journal.
Alphamers
Proprietary antibody recruiting molecules (ARMs) that redirect host immune responses through recruitment of pre-existing, abundant antibodies from the body’s natural repertoire to deliver precise and potent treatment of life-threatening indications.
CTX-187
Centauri's lead clinical candidate designed to combat clinically prevalent and multidrug-resistant Gram-negative bacterial infections using a dual mechanism-of-action combining immunotherapeutic effects and direct antibacterial activity.
CTX-187 (lead clinical candidate, ABX-01 programme)
Lead clinical-stage bifunctional antimicrobial immunotherapy designed to treat clinically prevalent and multidrug-resistant Gram-negative bacterial infections; combines direct antibacterial activity with recruitment of anti-glycan antibodies to activate complement and opsonophagocytosis. Progressed into Phase I clinical trials (first-in-human) and received QIDP designation.
CTX-09 (early proof-of-concept molecule)
Preclinical bifunctional molecule that demonstrated recruitment of anti‑glycan antibodies and immune‑mediated clearance of multidrug‑resistant Gram‑negative strains in vitro and in vivo; published in a peer‑reviewed journal.
Alphamers
Proprietary antibody recruiting molecules (ARMs) that redirect host immune responses through recruitment of pre-existing, abundant antibodies from the body’s natural repertoire to deliver precise and potent treatment of life-threatening indications.
CTX-187
Centauri's lead clinical candidate designed to combat clinically prevalent and multidrug-resistant Gram-negative bacterial infections using a dual mechanism-of-action combining immunotherapeutic effects and direct antibacterial activity.
Services
Collaborative research, grant partnerships, and licensing/partnership discussions to apply the immunotherapy platform across therapeutic indications.
Management and execution of grant-funded development projects and reporting to public and non-profit funders.
Collaborative research, grant partnerships, and licensing/partnership discussions to apply the immunotherapy platform across therapeutic indications.
Management and execution of grant-funded development projects and reporting to public and non-profit funders.
Expertise Areas
- Immunotherapy platform development
- Anti-infectives and antimicrobial resistance (AMR) therapeutics
- Preclinical efficacy and IND-enabling studies
- Phase I clinical development and first‑in‑human trials
Key Technologies
- Glycan-directed endogenous antibody recruitment
- Bifunctional therapeutic molecules
- Modular linker chemistry for targeted effector presentation
- Complement activation and opsonophagocytosis mechanisms
News & Updates
Listed attendance at an AMR-focused conference.
Listed attendance at an infectious diseases conference.
Peer-reviewed publication presenting preclinical proof-of-concept data for a bifunctional immunotherapy that recruits anti-glycan antibodies and demonstrated activity against MDR Gram-negative bacteria.
Announcement of Qualified Infectious Disease Product designation from the FDA for the lead clinical candidate.
Lead candidate in ABX-01 programme received Qualified Infectious Disease Product designation from the US FDA to support development of an antibacterial immunotherapy for Gram-negative infections.
Secured a £6M investment from AMR Action Fund, extending Series A to £30M to support Phase I and Phase II preparation.
Listed attendance at an AMR-focused conference.
Listed attendance at an infectious diseases conference.
Peer-reviewed publication presenting preclinical proof-of-concept data for a bifunctional immunotherapy that recruits anti-glycan antibodies and demonstrated activity against MDR Gram-negative bacteria.
Announcement of Qualified Infectious Disease Product designation from the FDA for the lead clinical candidate.
Lead candidate in ABX-01 programme received Qualified Infectious Disease Product designation from the US FDA to support development of an antibacterial immunotherapy for Gram-negative infections.
Secured a £6M investment from AMR Action Fund, extending Series A to £30M to support Phase I and Phase II preparation.